Anna J. Yssel
University Of Cape Town And National Health Laboratory Service
Cape Town, WC, South Africa
Cape Town, WC, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
VRC01 exerted differential pressure on HIV-1 Env from subtypes B and C that continued in the first weeks post-diagnosis in the AMP trials.
Journal: The Journal of infectious diseases
Published: March 17, 2026
Quantifying how HIV-1 envelope sequence features impact vaccine efficacy in the HVTN 705/HPX2008 randomised trial in southern African women.
Journal: EBioMedicine
Published: January 07, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.
Journal: Nature communications
Published: January 06, 2026
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV Infection.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection.
Journal: Nature communications
Published: November 14, 2025
Bayesian estimation of HIV acquisition dates for prevention trials.
Journal: mBio
Published: September 09, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2025
HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation.
Journal: bioRxiv : the preprint server for biology
Published: February 20, 2025
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.
Journal: Journal of virology
Published: January 16, 2025
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 19, 2024
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
Journal: PLoS pathogens
Published: January 27, 2023
Last Updated: 09/26/2026